Kintor Pharmaceutical (HKSE:09939) Debt-to-Equity : 0.55 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Debt-to-Equity?

Kintor Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$129.32 Mil. Kintor Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$148.42 Mil. Kintor Pharmaceutical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$501.07 Mil. Kintor Pharmaceutical's debt to equity for the quarter that ended in Dec. 2023 was 0.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kintor Pharmaceutical's Debt-to-Equity or its related term are showing as below:

HKSE:09939' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.18 Max: 0.55
Current: 0.55

During the past 6 years, the highest Debt-to-Equity Ratio of Kintor Pharmaceutical was 0.55. The lowest was 0.10. And the median was 0.18.

HKSE:09939's Debt-to-Equity is ranked worse than
76.4% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:09939: 0.55

Kintor Pharmaceutical Debt-to-Equity Historical Data

The historical data trend for Kintor Pharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Debt-to-Equity Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.15

0.10

0.19

0.55

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.10	0.20	0.19	0.24	0.55

Competitive Comparison of Kintor Pharmaceutical's Debt-to-Equity

For the Biotechnology subindustry, Kintor Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintor Pharmaceutical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's Debt-to-Equity falls into.

Kintor Pharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kintor Pharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(129.317	+	148.415)	/	501.073
	=	0.55

Kintor Pharmaceutical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(129.317	+	148.415)	/	501.073
	=	0.55

Kintor Pharmaceutical (HKSE:09939) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kintor Pharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical (HKSE:09939) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KNTPF:USA

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.

Executives

Tong Youzhi	2101 Beneficial owner
Kt International Investment Limited	2101 Beneficial owner
Guo Chuangxing	2201 Interest of corporation controlled by you
Kg Development Limited	2101 Beneficial owner
Nomura Holdings, Inc.	2201 Interest of corporation controlled by you
Tong Youzhi	2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si	2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si	2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines